{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:24:17Z","timestamp":1793298257996,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tapinarof is a non\u2010steroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream (1%) in Japanese patients aged \u226518\u2009years with plaque psoriasis in two phase 3 trials, ZBA4\u20101 and ZBA4\u20102. ZBA4\u20101 (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009158) consisted of a 12\u2010week, double\u2010blind, vehicle\u2010controlled treatment period (period 1) and a 12\u2010week extension treatment period (period 2). Patients were randomized 2:1 to tapinarof or vehicle in period 1; subsequently, all patients who were enrolled in period 2 received tapinarof. ZBA4\u20102 (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009305) was a 52\u2010week, open\u2010label, uncontrolled trial in which all patients received tapinarof. In period 1 of ZBA4\u20101, the proportion of patients who achieved a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) with \u22652\u2010grade improvement from baseline at week 12 (PGA treatment success, the primary endpoint) was 20.06% in the tapinarof group and 2.50% in the vehicle group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0035). The proportion of patients with \u226575% improvement from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (PASI75 response, a key secondary endpoint) was 37.7% in the tapinarof group and 3.8% in the vehicle group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). In ZBA4\u20102, PGA treatment success rate was 30.0% at week 12, 51.3% at week 24, and 56.3% at week 52, and PASI75 response rate was 50.4% at week 12, 77.5% at week 24, and 79.9% at week 52, indicating that efficacy responses improved over time and were maintained over 52\u2009weeks. Across the two trials, most adverse events (AEs) were mild or moderate; common AEs included folliculitis and contact dermatitis. In summary, tapinarof cream (1%) was efficacious and generally safe for up to 52\u2009weeks of treatment in Japanese patients with plaque psoriasis.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17423","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T09:08:17Z","timestamp":1723799297000},"page":"1269-1278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials"],"prefix":"10.1111","volume":"51","author":[{"given":"Atsuyuki","family":"Igarashi","sequence":"first","affiliation":[{"name":"Igarashi Dermatology Higashigotanda  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Research and Clinical Center for Yusho and Dioxin Kyushu University  Fukuoka Japan"},{"name":"Department of Dermatology, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3506-9868","authenticated-orcid":false,"given":"Shuichi","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Japan Tobacco Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Murata","sequence":"additional","affiliation":[{"name":"Japan Tobacco Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamane","sequence":"additional","affiliation":[{"name":"Japan Tobacco Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_9_4_1","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman SR","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.004"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7481"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7317"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215424"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.037"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.181"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/69804"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.022"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1620"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00205.x"},{"key":"e_1_2_9_22_1","first-page":"1323","article-title":"On the variance estimator for the Mantel\u2010Haenszel risk difference","volume":"45","author":"Sato T","year":"1989","journal-title":"Biometrics"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00641-4"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01008-9"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6627"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16246"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.047"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.135"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:23:14Z","timestamp":1727925794000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/1346-8138.17423"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17423","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"2024-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}